HCW Biologics Inc. HCWB
Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026
HCW Biologics Inc. (HCWB) is a healthcare company listed in the US with a market value of about $2M. In the twelve months to June 30, 2026 it had revenue of $7M and net income of -$6M, a net margin of -83.0%.
Its overall Stock Analiz score is 0.2 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -58% a year, a 5-year average ROIC of -1032%.
About HCW Biologics
HCW Biologics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2021. Revenue went from $4M in 2020 to $54232 in 2025, a decline of about 57.9% a year. It was profitable in 0 of the last 6 years in our data. Its share count rose by 134% over three years (dilution for shareholders). It spends 10036% of revenue on research and development.
Score: 0.2 / 5
Checks passed
- Strong R&D investment or growth above 20%
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $7M | $54232 | $3M | $3M | $7M | $0 | $4M |
| Net income | -$6M | -$8M | -$30M | -$25M | -$15M | -$13M | -$6M |
| Free cash flow | — | -$13M | -$14M | -$29M | -$21M | -$11M | -$11M |
| EPS (diluted) | $-2.66 | $-10.63 | $-30.96 | $-28.00 | $-16.80 | $-27.60 | $-59.60 |
| Net margin | -83.0% | -14677.1% | -1169.7% | -879.5% | -221.7% | — | -141.5% |
| ROIC | — | -137.5% | -4847.3% | -129.9% | -19.9% | -26.1% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does HCW Biologics pay a dividend?
Not currently.
Is HCW Biologics a good stock to buy?
We do not give buy or sell advice. HCW Biologics scores 0.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.